Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Endocrine Reviews · 2024
DOI: 10.1210/endrev/bnad026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Reviews, 2024. Verfasst von Nathan Mullen und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway H91V4AY, Ireland. Hauptthemen laut MEDLINE: Hyperaldosteronism, Adrenocortical Adenoma, Hypertension. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 285 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIBIB NIH HHS, Science Foundation Ireland, NIH HHS.
Abstract (Originalsprache)
Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with increased morbidity and mortality when compared with blood pressure–matched cases of primary hypertension. Current limitations in patient care stem from delayed recognition of the condition, limited access to key diagnostic procedures, and lack of a definitive therapy option for nonsurgical candidates. However, several recent advances have the potential to address these barriers to optimal care. From a diagnostic perspective, machine-learning algorithms have shown promise in the prediction of PA subtypes, while the development of noninvasive alternatives to adrenal vein sampling (including molecular positron emission tomography imaging) has made accurate localization of functioning adrenal nodules possible. In parallel, more selective approaches to targeting the causative aldosterone-producing adrenal adenoma/nodule (APA/APN) have emerged with the advent of partial adrenalectomy or precision ablation. Additionally, the development of novel pharmacological agents may help to mitigate off-target effects of aldosterone and improve clinical efficacy and outcomes. Here, we consider how each of these innovations might change our approach to the patient with PA, to allow more tailored investigation and treatment plans, with corresponding improvement in clinical outcomes and resource utilization, for this highly prevalent disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway H91V4AY, Ireland.
- Department of Electrical and Computer Engineering, Kansas State University, Manhattan, KS 66506, USA.
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Wellcome-MRC Institute of Metabolic Science, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.
ORCID-Profile: Nathan Mullen, Irina Bancos, Mark Gurnell, Michael C Dennedy
Förderung
- NIBIB NIH HHS
- Science Foundation Ireland
- NIH HHS
- National Institutes of Health
- NIHR
- Cambridge Biomedical Research Centre
Zitieren
APA
Mullen, N., Curneen, J., Donlon, P. T., Prakash, P., Bancos, I., Gurnell, M., & Dennedy, M. C. (2024). Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks. Endocrine Reviews. https://doi.org/10.1210/endrev/bnad026
Vancouver
Mullen N, Curneen J, Donlon PT, Prakash P, Bancos I, Gurnell M, et al. Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks. Endocrine Reviews. 2024. doi:10.1210/endrev/bnad026
BibTeX
@article{Mullen2024,
author = {Mullen, Nathan and Curneen, James and Donlon, Padraig T and Prakash, Punit and Bancos, Irina and Gurnell, Mark and Dennedy, Michael C},
title = {Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks},
journal = {Endocrine Reviews},
year = {2024},
doi = {10.1210/endrev/bnad026}
}
EUVIMED